Survival benefit of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer recurrence after completely pulmonary resection

BACKGROUND: Selected patients in non-small cell lung cancer (NSCLC) responded to the treatment of immune checkpoint inhibitors (ICIs) have the survival benefit for advanced stages or metastatic status. METHODS: We investigated whether a response to ICI monotherapy since 2016 influences the survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuroda, Hiroaki, Takahashi, Yusuke, Shirai, Suguru, Takahara, Hirotomo, Nakada, Takeo, Sakakura, Noriaki, Matsushita, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421933/
https://www.ncbi.nlm.nih.gov/pubmed/34532362
http://dx.doi.org/10.21037/atm-21-1492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421933/
https://www.ncbi.nlm.nih.gov/pubmed/34532362
http://dx.doi.org/10.21037/atm-21-1492

Ejemplares similares